Ten Cancer-Related Breakthroughs Giving Us Hope in 2026
More Than 145 Dana-Farber Affiliated Faculty Named as 2026 Top Doctors™ in Boston Magazine
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
Dana-Farber Researchers Create Experimental AI-based Oncologist’s Assistant
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors
Seeing Is Believing
Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
Twenty-Five Years of Progress in Cancer
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
A Routine Blood Test Could Help Predict Who Benefits Most from CAR T-Cell Therapy
Showing 31 - 45 of 1027 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...69 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
